Floatz logo

CRA-027483

Pancreatic Cancer

Pharmacyclics LLC.Small moleculePhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
59/ 100

Competitive context

382 Active assets in the Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

CRA-027483 is also rated in:

pancreatic ductal adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
exocrine pancreatic carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →